Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Recommendation of "Buy" by Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) have earned a consensus rating of "Buy" from the nine research firms that are covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $15.97.

A number of equities research analysts have issued reports on VYGR shares. Leerink Partnrs raised shares of Voyager Therapeutics to a "strong-buy" rating in a report on Wednesday, October 16th. Canaccord Genuity Group reissued a "buy" rating and set a $14.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. Wedbush assumed coverage on Voyager Therapeutics in a report on Friday, November 29th. They set an "outperform" rating and a $11.00 target price for the company. Leerink Partners initiated coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They set an "outperform" rating and a $15.00 price target on the stock. Finally, HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th.

Insider Buying and Selling at Voyager Therapeutics

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the sale, the chief operating officer now owns 112,328 shares of the company's stock, valued at $634,653.20. The trade was a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.53% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Voyager Therapeutics

A number of large investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. lifted its stake in Voyager Therapeutics by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company's stock worth $61,000 after purchasing an additional 4,098 shares during the last quarter. Intech Investment Management LLC purchased a new position in shares of Voyager Therapeutics in the third quarter worth about $74,000. Victory Capital Management Inc. lifted its stake in shares of Voyager Therapeutics by 14.5% in the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company's stock valued at $102,000 after acquiring an additional 1,630 shares during the last quarter. Hsbc Holdings PLC purchased a new stake in Voyager Therapeutics during the 2nd quarter valued at about $128,000. Finally, Verition Fund Management LLC bought a new position in Voyager Therapeutics during the 3rd quarter worth approximately $216,000. 48.03% of the stock is owned by hedge funds and other institutional investors.

Voyager Therapeutics Trading Down 4.9 %

Shares of VYGR stock traded down $0.28 on Friday, hitting $5.45. 615,352 shares of the stock were exchanged, compared to its average volume of 407,542. The firm's 50 day moving average is $6.09 and its two-hundred day moving average is $6.81. Voyager Therapeutics has a one year low of $5.19 and a one year high of $10.66. The firm has a market capitalization of $297.71 million, a PE ratio of 7.68 and a beta of 0.93.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.29. The firm had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter last year, the business earned ($0.59) earnings per share. On average, sell-side analysts expect that Voyager Therapeutics will post -0.89 earnings per share for the current year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.